Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Follow that CAR! Dutch prospective cohort of CAR T-cell therapy referral and treatment for B-cell malignancies
NL-OMON51188Recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jul 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Small Molecules
- Countries
- 1
01
Overview
Open-label trial of itacitinib + axicabtagene ciloleucel in B-cell malignancy, diffuse large B-cell lymphoma (DLBCL), acute lymphoblastic leukemia (ALL) and 1 more (2 cohorts), sponsored by Amsterdam University Medical Center. Primary endpoints: Tumor board referral and eligibility assessment data, Overall survival and 18 more. Started Jul 2022; status: recruiting.
02
Drugs
itacitinib + axicabtagene ciloleucel
03
Conditions
B-cell malignancydiffuse large B-cell lymphoma (DLBCL)acute lymphoblastic leukemia (ALL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NL-OMON51188.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51188.